We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

3 great income stocks I’d buy today

If you are looking for a base rate busting income these three FTSE 100 companies are a great place to start, says Harvey Jones.

| More on:

You’re reading a free article with opinions that may differ from The Twelfth Magpie’s Premium Investing Services. Become a member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more, and get a free 'Best Buy Now' stock!.

The earlier you start investing in income-generating stocks, the sooner those dividends will start piling up, and the richer you will ultimately be. Here are three great FTSE 100 income stocks that I would consider buying today. 

AstraZeneca

Before you put any money into AstraZeneca (LSE: AZN) you have to consider the small matter of its recent profit warning. The pharmaceuticals giant warned that cheaper generic versions of its cholesterol drug Crestor are continuing to eat into sales, triggering a 13% decline in revenues in the fourth quarter, with annual turnover falling 7% to £23bn.

Should you buy AstraZeneca Plc shares today?

Before you decide, please take a moment to review this report first. Despite ongoing uncertainties from US tariffs to global conflicts, Mark Rogers and his team believe many UK shares still trade at substantial discounts, offering savvy investors plenty of potential opportunities to learn about.

That’s why this could be an ideal time to secure this valuable research – Mark’s analysts have scoured the markets to reveal 5 of his favourite long-term ‘Buys’. Please, don’t make any big decisions before seeing them.

The big hope now is that AstraZeneca can replenish its dwindling pipeline with a new generation of blockbusters. Chief executive Pascal Soriot knows this better than anybody, and next year we will discover whether his strategy of investing in a dozen or so new drugs will pay off.

Soriot is aiming to almost double company revenues to reach as much as $45bn by 2023 and says AstraZeneca is rapidly approaching the “inflection point“, with 12 drugs in the final stage of development, including cancer and asthma treatments. If they succeed, the rewards will flow. You get a healthy 4.73% yield while you wait for the answer, but AstraZeneca may be too risky for some.

National Grid

Utility company National Grid (LSE: NG) offers a similar-sized yield of 4.52%, but with fewer risks, as it is a heavily regulated industry offering a basic service to millions of customers in the UK and north-eastern US. This assures relatively steady earnings and cash flows.

This gives management the confidence to pledge to increase its dividend each year in line with the retail price index, which stood at 2.5% in December. Investors also benefit from share buybacks and special dividends, with the company recently announcing plans to sell a majority stake in its gas distribution business and return £4bn from the sale to shareholders. Share price growth has been steady too, up 50% in five years, although it has wobbled lightly. This remains one of my favourite income stocks.

Persimmon

Housebuilders have had a bumpy ride since Brexit, Persimmon (LSE: PSN) included. But it has recovered lately, rising 17% in the last six months as the UK economy, population and house prices have continued to grow.

The housing crisis is one of the biggest problems facing Britain and few believe the government has the answers, following the publication of last week’s Housing White Paper, widely seen as a damp squib. This was seen as good news for housebuilders, as the clamour for property looks set to continue. Persimmon rose 3.47% on Wednesday as a result, faster than any housebuilder.

Perhaps Brexit will slow population growth, perhaps not. Perhaps interest rates will rise spark a crash, but I doubt it. House price growth is certainly slowing, falling to 5.7% a year in January, down from a high of 10% last March, Halifax says. But I am still backing UK property, a scarce resource, especially with Persimmon trading at just 11.5 times earnings and yielding 5.57%, which is more than 22 times base rate.

Harvey Jones has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young female couple boarding their plane at the airport to go on holiday.
Investing Articles

Can the Rolls-Royce share price reach £15.97 by the end of August?

The Rolls-Royce share price has had a solid run in the last year. Muhammad Cheema takes a look at whether…

Read more »

Santa Clara offices of NVIDIA
Investing Articles

Up 1,200% in 5 years, here’s why Nvidia could still be a brilliant value stock

An exciting new announcement that could reshape the PC industry has just pushed Nvidia stock... well, just about nowhere really.

Read more »

House models and one with REIT - standing for real estate investment trust - written on it.
Investing Articles

How investing £4.50 a day could set you on the way to a £1,505 monthly second income

How can UK stocks with high dividend yields help investors earn a meaningful second income from the price of a…

Read more »

Investing Articles

Up 103% with a P/E of 261 — is this FTSE 100 stock still worth buying?

One FTSE 100 stock is quietly moving higher while most investors are still looking elsewhere — is the market missing…

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

The smart money thinks AI stocks look risky — but is there still a chance to buy?

According to fund managers, the AI trade is getting crowded. But they still seem to think it’s the place to…

Read more »

Man putting his card into an ATM machine while his son sits in a stroller beside him.
Investing Articles

Barclays shares are 11% below their 52-week high. Could they be a bit of a bargain to consider?

Overpriced or one of the FTSE 100’s hidden gems? James Beard takes a closer look at how the market is…

Read more »

Stack of one pound coins falling over
Investing Articles

Down 65% but yielding 6.7% – is this beaten-down UK stock now a generational bargain?

Harvey Jones says this UK stock is one of the worst FTSE 100 performers but there are sound reasons to…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

Is this FTSE stock really 46% undervalued?

Analysts reckon this FTSE stock should be worth nearly 50% more. James Beard considers why there’s so much positivity surrounding…

Read more »